AKT1 and prostate neoplasm: Previously we reported that a selective PIP5K1α inhibitor, ISA-2011B, blocked the PI3K/AKT pathway by decreasing AKT phosphorylation at Serine 473 (pAKT S473), leading to reduced growth of aggressive prostate tumors in a xenograft mouse model [15, 16].